SEngine Precision Medicine and Atomwise Announce Strategic Joint Venture to Accelerate Novel Drug Discovery

SEATTLE, Wash. & SAN FRANCISCO, Calif.–(BUSINESS WIRE)– Joint venture brings together AI technology and living tumor organoids to develop novel personalized therapies for cancer patients SEngine Precision Medicine and Atomwise, Inc. today announced a joint venture to accelerate novel oncology drug discovery utilizing the unique platform technologies each company […]

View Original Source at SEngine Precision Medicine and Atomwise Announce Strategic Joint Venture to Accelerate Novel Drug Discovery